Date: 09th July, 2026
Regulatory Compliance Filing
Balaxi Pharmaceuticals Limited submitted a mandatory compliance report to the National Stock Exchange of India Limited. The filing was made pursuant to SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated 30th January, 2026.
The report, received from the company's Registrar and Share Transfer Agent (RTA), M/s. Aarthi Consultants Private Limited, covers the period ended June 2026. It specifically addresses the re-lodgement of transfer requests for physical shares under a special window provided by the SEBI circular.
RTA Report Details
The enclosed report from Aarthi Consultants Private Limited, dated 06/07/2026, provides the following status as of June 2026:
- Number of requests received during the month: NIL
- Number of requests processed during the month: NIL
- Number of requests approved during the month: NIL
- Number of requests rejected during the month: NIL
- Average time taken for processing of requests: NA
Disclosure and Availability
The company confirmed that this report is for the information and records of the National Stock Exchange. The same information is also available on the company's website at www.balaxipharma.in.
Signatory and Officer Information
The submission was digitally signed by Aman Purohit, who holds the designation of Company Secretary & Compliance Officer. His ICSI Membership Number is A59345.
The report from the RTA was signed by Jagan Mohan Gobburi, who is identified as the Compliance Officer for Aarthi Consultants Pvt Ltd.
No material disclosures under the following sections: KMP / Board / Auditor Changes, Dividend Declaration, Board Meeting Outcomes, Financial Results, Auditor’s Report, Disinvestment / Strategic Actions, Media Release / Investor Communication.